Moderna Shares Fall 11%, Eye Worst Week Since August 2025 After June Surge
Moderna shares fell 11% on Friday, eyeing their worst week since August 2025 after a June surge. An FDA panel voted 9-0 for its mRNA-1010 flu vaccine, with a decision due by August 5.
Moderna Inc. shares fell 11% on Friday and were on track for their worst week since August 2025, pulling back after a rally that had pushed the shares above $85 earlier in the month. The pullback appears driven by a mix of profit-taking and cautious Wall Street comments after a whopping 48% rally in June and a smaller 3% rally in May.
Moderna confirmed in June that its seasonal flu vaccine candidate, mRNA-1010, remains on track for a regulatory decision by August 5. This follows the FDA's Vaccines and Related Biological Products Advisory Committee's unanimous 9-0 vote recommending approval for use in adults 50 years and older. Second-quarter earnings, due July 31, will offer updates on revenue trends and launch plans. Later this year, investors will watch for late-stage data on the company's individualized cancer therapy in melanoma and potential approvals for its updated COVID-19 vaccine in Europe and other markets. Moderna continues to target cash breakeven by 2028.
On Stocktwits, retail sentiment around MRNA stock stayed within the bearish territory over the past 24 hours, while message volume remained at normal levels. According to the platform's internal data, retail chatter has risen by about 280% over the past 30 days. MRNA stock has gained by about 132% year-to-date.